Afficher la notice abrégée

dc.contributor.authorSant, Milena
dc.contributor.authorSánchez Pérez, María José 
dc.contributor.authorMelanoma HR Study Working Group
dc.date.accessioned2022-10-14T08:50:24Z
dc.date.available2022-10-14T08:50:24Z
dc.date.issued2022-09-08
dc.identifier.citationSant, M... [et al.]. Association of Sentinel Node Biopsy and Pathological Report Completeness with Survival Benefit for Cutaneous Melanoma and Factors Influencing Their Different Uses in European Populations. Cancers 2022, 14, 4379. [https://doi.org/10.3390/cancers14184379]es_ES
dc.identifier.urihttps://hdl.handle.net/10481/77316
dc.description.abstractObjectives: Standard care for cutaneous melanoma includes an accurate pathology report (PR) and sentinel lymph node biopsy (SLNB) for staging clinically node-negative >1 mm melanomas. We aimed to investigate the frequency of these indicators across European countries, also assessing consequences for survival. Methods: We analyzed 4245 melanoma cases diagnosed in six European countries in 2009–2013. Multivariable logistic regression was used to estimate the Odds Ratio (OR) of receiving complete PR with eight items or SLNB and model-based survival to estimate the five-year relative excess risks of death (RER). Results: Overall, 12% patients received a complete PR (range 2.3%, Estonia—20.1%, Italy); SLNB was performed for 68.8% of those with cN0cM0 stage (range 54.4%, Spain—81.7%, Portugal). The adjusted OR of receiving a complete PR was lower than the mean in Estonia (OR 0.11 (0.06–0.18)) and higher in Italy (OR 6.39 (4.90–8.34)) and Portugal (OR 1.39 (1.02–1.89)); it was higher for patients operated on in specialized than general hospitals (OR 1.42 (1.08–1.42)). In the multivariate models adjusted for age, sex, country and clinicalpathological characteristics, the RER resulted in being higher than the reference for patients not receiving a complete PR with eight items (RER 1.72 (1.08–2.72)), or for those not undergoing SLNB (RER 1.76 (1.26–2.47)) Patients with non-metastatic node-negative thickness >1 mm melanoma who did not undergo SLNB had a higher risk of death (RER (RER 1.69 (1.02–2.80)) than those who did. Conclusions: Accurate pathology profiling and SLNB carried survival benefit. Narrowing down between-countries differences in adhesion to guidelines might achieve better outcomes.es_ES
dc.description.sponsorshipItalian Ministry of Health “Ricerca Corrente”es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCutaneous melanomaes_ES
dc.subjectPopulation-based cancer registrieses_ES
dc.subjectPathology reportes_ES
dc.subjectSentinel lymph node biopsyes_ES
dc.subjectRelative survivales_ES
dc.subjectExcess of relative risk of deathes_ES
dc.titleAssociation of Sentinel Node Biopsy and Pathological Report Completeness with Survival Benefit for Cutaneous Melanoma and Factors Influencing Their Different Uses in European Populationses_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/cancers14184379
dc.type.hasVersionVoRes_ES


Fichier(s) constituant ce document

[PDF]

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

Atribución 4.0 Internacional
Excepté là où spécifié autrement, la license de ce document est décrite en tant que Atribución 4.0 Internacional